Immunotherapy harnesses the body\’s own immune system to fight cancer and it is revolutionizing cancer treatment. Unprecedented outcomes have been observed in cancers that were once perceived as hopeless such as melanoma and lung cancer. Nonetheless, not all patients respond to treatment, and an understanding of efficacy drivers is lacking. Can co-clinical trials provide the necessary mechanistic insight to identify the right immunotherapies and combinations to improve patient outcomes and speed up drug approvals?

Johnson & Johnson Innovation, JLABS (JLABS) is bringing together top experts to discuss the latest developments, challenges, and opportunities with the co-clinical approach to immunotherapy development. Join Dr. Wendy Garrett and Dr. Kwok-Kin Wong as they present the latest research in this area and engage in a panel discussion to obtain insights into novel immunotherapies of the future.

Agenda:
2:00pm | Registration Opens
2:30pm | Presentations
3:15pm | Panel discussion
4:00pm | Reception
4:30pm | Close

Speakers:
Wendy Garrett | Associate Professor, Immunology & Infectious Diseases, Harvard T. H. Chan School of Public Health read bio»
Kwok-Kin Wong | Professor of Medicine, Dana-Farber Cancer Institute/Harvard Medical School read bio»
[moderator] Kathryn Packman | Scientific Director Oncology Collaborations, Janssen Research & Development, LLC read bio»

Fees:
$25 | General Public
$15 | Student/Academic
$35 | At the door

Location:
JLABS @LabCentral
700 Main St
Cambridge, MA 02139

About the Science First series:
The purpose of the Science First series, sponsored by Johnson & Johnson Innovation, JLABS, is to bring together top experts to explore a pressing topic in their scientific field. It is a chance for local scientists, researchers, and entrepreneurs to present and dialogue on new discoveries, advancing techniques, and other cutting-edge science themes.